BIA
CRNX

Bell Investment Advisors’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bell Investment Advisors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$637 Hold
17
– – ﹤0.01% 1653
2026
Q1 		$618 Hold
17
– – ﹤0.01% 1672
2025
Q4 		$792 Sell
17
-10
-37% -$445 ﹤0.01% 1603
2025
Q3 		$1.13K Buy
27
+17
+170% +$544 ﹤0.01% 1528
2025
Q2 		$288 Sell
10
-15
-60% -$463 ﹤0.01% 1834
2025
Q1 		$839 Hold
25
– – ﹤0.01% 1610
2024
Q4 		$1.28K Hold
25
– – ﹤0.01% 1508
2024
Q3 		$1.28K Buy
25
+10
+67% +$516 ﹤0.01% 1518
2024
Q2 		$672 Buy
+15
New +$693 ﹤0.01% 1717

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bell Investment Advisors's CRNX Position: Q2 2026 in Review

Bell Investment Advisors held its Crinetics Pharmaceuticals (CRNX) position steady in Q2 2026 at 17 shares worth $637. The position accounts for ﹤0.01% of the portfolio, ranked #1653.

Bell Investment Advisors first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. The position peaked at $1.28K in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Bell Investment Advisors held 17 shares of Crinetics Pharmaceuticals worth $637 as of Q2 2026.
  • Bell Investment Advisors left its Crinetics Pharmaceuticals share count unchanged in Q2 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Bell Investment Advisors's portfolio in Q2 2026, its #1653 holding.
  • Bell Investment Advisors first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • Bell Investment Advisors's Crinetics Pharmaceuticals position peaked at $1.28K in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Bell Investment Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.